Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579168 | 0.85 | KDR (0.43) | GCKMAPK14METKDRBRAF | |
| SCHEMBL5579083 | 0.81 | HTR2A (0.41) | GCKKDRBRAFAXL | |
| SCHEMBL5579007 | 0.80 | UBE2M (0.41) | GCKKDRBRAF | |
| SCHEMBL1726557 | 0.80 | MAPK14 (0.44) | MAPK14PTK2METBRAF | |
| SCHEMBL13860967 | 0.80 | MAPK14 (0.47) | GCKMAPK14MAPK13KDRBRAF | |
| SCHEMBL5579155 | 0.80 | MAPK14 (0.41) | GCKMAPK14METKDRBRAF | |
| SCHEMBL4321743 | 0.79 | MET (0.59) | GCKMAPK14RIOK2MAPK13MET | |
| SCHEMBL5579006 | 0.79 | KDR (0.48) | GCKMAPK14METCSF1RKDR | |
| SCHEMBL4335060 | 0.78 | MAPK14 (0.54) | GCKMAPK14MAPK13KDRBRAF | |
| SCHEMBL5579128 | 0.78 | MET (0.50) | MAPK14METKDRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | GCK 1008/4885MAPK14 2269/4885PTK2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.